Skip to main content
Clinical Trials/NCT02700165
NCT02700165
Completed
Not Applicable

Non-Invasive Fat Reduction in the Chin Using Cryolipolysis

Zeltiq Aesthetics1 site in 1 country14 target enrollmentFebruary 2016

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Body Fat Disorder
Sponsor
Zeltiq Aesthetics
Enrollment
14
Locations
1
Primary Endpoint
Proportion of Accurately Identified Pre-Treatment Photos by a Panel of Blinded Independent Reviewers
Status
Completed
Last Updated
4 years ago

Overview

Brief Summary

The purpose of this study is to further evaluate the safety and efficacy of non-invasive reduction of subcutaneous fat in the submental and submandibular area using Cryolipolysis.

Registry
clinicaltrials.gov
Start Date
February 2016
End Date
December 2016
Last Updated
4 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Sponsor
Zeltiq Aesthetics
Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Not provided

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Proportion of Accurately Identified Pre-Treatment Photos by a Panel of Blinded Independent Reviewers

Time Frame: Baseline (pre-treatment) and 12 weeks post treatment

Change in the treated vs. untreated areas will be assessed by observation of changes in surface contour and/or fat volume by an independent photo review of pre-treatment and post-treatment images of the treated areas. Reviewers will be practicing dermatologists or plastic surgeons. All reviewers will be blinded to post-treatment vs. baseline untreated area. The order in which images will be presented will be randomized; for each subject placement of the baseline, pre-treatment image will be randomized for each pair of subject images. Reviewers will be asked to select the baseline photos for each subject photo series and record selections on a data collection form. Success is defined as 70% correct identification of pre-treatment images by at least 70% correct identification of pre-treatment images by two out of three reviewers.

The Number of Unanticipated Adverse Device Effects (UADE) Reported

Time Frame: Enrollment through the 12 week final follow-up visit

The primary safety endpoint is the count of unanticipated adverse device effects (UADEs) reported in the study period. It is expected there will be zero UADEs.

Secondary Outcomes

  • Subject Satisfaction(12 weeks post-treatment)
  • Change in Fat Layer Thickness of the Submental Area as Measured by Caliper(Baseline and 12 week post-treatment)

Study Sites (1)

Loading locations...

Similar Trials